Position in GNLX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$42,284
New position
Shares Held
17,473
first reported quarter
Ownership
0.039%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026NINE MASTS CAPITAL Ltd holds $7,439,566 across 35 Biotechnology names. GNLX ranks #17 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APLS |
Apellis Pharmaceuticals, Inc.
|
97,478 | $3,921,539 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
11,010 | $1,070,722 | |
| 3 | ABVX |
Abivax S.A.
|
7,500 | $835,125 | |
| 4 | LNAI |
Lunai Bioworks Inc.
|
102,426 | $334,318 | |
| 5 | GALT |
Galectin Therapeutics Inc
|
19,324 | $53,913 | |
| 6 | BMEA |
Biomea Fusion, Inc.
|
32,472 | $49,682 | |
| 7 | OTLK |
Outlook Therapeutics, Inc.
|
232,546 | $47,904 | |
| 8 | PRQR |
ProQR Therapeutics N.V.
|
29,518 | $47,819 |
All Filings in GNLX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $42,284 | 17,473 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||